Skip to main content
TipRanks
Go Ultimate75% OFF

Alan Brian Collier Insider Profile

4 Followers

Alan Brian Collier, CEO at Endonovo Therapeutics, holds 26.22K shares in Endonovo Therapeutics (Ticker: ENDV). Most recently, Alan Brian Collier Bought 400 shares of Endonovo Therapeutics on Jul 07, 2020 for an estimated value of $40.00.

Alan Brian Collier's Trading History

ENDV
Endonovo Therapeutics
Jul 07, 2020CEOInformative Buy40.00―
ENDV
Insider Shares: 26.22K (0.25%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Jul 07, 2020Informative Buy$40.00400$0.10-61.10%
Feb 26, 2020Informative Buy$96.00100$0.96-93.10%
Jan 23, 2020Informative Buy$400.00200$2.00-95.70%
Dec 31, 2019Uninformative Buy$0.005,700$0.00―
Dec 09, 2019Uninformative Buy$0.0015,000$0.00―

You May Also Like

Alan Brian Collier insider profile FAQ

What is the percentage of profitable transactions made by Alan Brian Collier?
The percentage of profitable transactions made by Alan Brian Collier is 2%.
What is the average return per transaction made by Alan Brian Collier?
The average return per transaction made by Alan Brian Collier is -70.40%.
What stocks does Alan Brian Collier hold?
Alan Brian Collier holds: ENDV stocks.
What was Alan Brian Collier’s latest transaction?
Alan Brian Collier’s latest transaction was an Informative Buy of $40.00.
What was Alan Brian Collier's most profitable transaction?
Alan Brian Collier’s most profitable transaction was an Informative Buy of ENDV stock on April 24, 2019. The return on the trade was 8.90%.
What is Alan Brian Collier's role in Endonovo Therapeutics?
Alan Brian Collier's role in Endonovo Therapeutics is CEO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.